Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.
Plus incubation, consultancy, and advisory for this emerging field. ∎
Join thousands of psychedelic insiders…
For in-depth analysis and insights, consider our premium offering…
Our data and insights are cited in…
Consultancy, advisory and incubation offerings for investors, entrepreneurs, and beyond.
Our data and insights are cited in…
Delix Therapeutics Posts Early Efficacy Signal for ‘Non-Hallucinogenic’ Neuroplastogen as FDA Clears At-Home Phase II • NRx Pharmaceuticals Wants FDA to Ban Its Competitors’ Ketamine • Cybin Trades Toxic Financing for Top Tier Investors in $175M Raise • and more…
Each quarter, we provide a look at federal lobbying disclosures by psychedelic drug developers and nonprofits. Here, we share our analysis of the latest developments for our Pα+ subscribers.
AbbVie Officially Enters Psychedelics as Gilgamesh Deal Closes, Patent Dispute Opens • BPL-003 Wins Breakthrough Status as atai Raises $150M • FDA Passes on Psychedelics in First Round of Priority Vouchers • California’s Newsom Signs AB 1103, Easing Review Bottleneck for Psychedelic Studies • Funding Lags Sentiment…. Or Does It? and more…
Pα+ subscribers receive regular Bulletins, articles, interviews with insiders and quick-take analysis of major stories and developments (e.g., significant trial results, financing rounds, policy reforms, etc.); along with access to our back catalogue and Library.
INCUBATION & GROWTH
Whether you’re at the idea-formation stage or raising early-stage funding, we’re here to help across the entire psychedelic value chain and company life-cycle.
ADVISORY & CONSULTANCY
We help investors and corporates of all stripes understand and support the psychedelics space: from syndicates and VCs through to institutions.
INSIGHTS & ANALYSIS
Join our newsletter to stay abreast of the rapidly emergent psychedelics industry: from clinical trials and patents through to healing centres and decriminalisation.
After a half-century of prohibition, psychedelics are once again entering the mainstream.
Today’s so-called “psychedelic renaissance” is represented by a seemingly exponential increase in research and development activity, billions of dollars of funding, psychedelic policy reform initiatives and successes across the world, and changing public perceptions. ∎
Clinical trials involving psychedelics started, per year
Phase 3 studies of several psychedelics are underway.
Psychedelic policy reforms are gaining pace at the federal, state and local level in the U.S. and internationally.
of psychiatrists agreed that psychedelics show promise in treating psychiatric disorders.
Barnett et al., 2023
‘Alpha’, in the investing world, refers to an excess return on investment relative to a benchmark. But we broaden the definition of alpha on both ends to include more than just economic returns on more than just economic investments.
Instead, we conceptualise alpha as the excess return on myriad investments that people may make in the present and future of psychedelics: beyond economic capital, people might invest time, energy, and effort, for example. And that excess return might not be (purely) financial, it might also be realised through a more impactful treatment paradigm for mental health, for example, where the ‘benchmark’ is the inadequate status quo.
All this to say, we’re not only for investors. In fact, most of our readers aren’t: many of them are practitioners, regulators, entrepreneurs, and so on. ∎
Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond
Insights and interviews delivered to your inbox. No spam, just valuable information.
